search
Back to results

Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome

Primary Purpose

Metabolic Syndrome

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Methionine deficient diet
Methionine sufficient diet
Sponsored by
Pennington Biomedical Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring Methionine, Metabolic syndrome, Glucose Metabolism, Amino acid, Insulin clamp

Eligibility Criteria

21 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male or female between the ages of 21 to 60, inclusive
  • Waist greater than 40 inches for men and 35 inches for women
  • Weight has been stable for at least 6 months (no more than 5 pounds gained or lost)
  • For women of childbearing potential: subject must be willing to use acceptable form of contraception (pill, condom, diaphragm etc.)
  • At least 2 of the following:

HDL cholesterol

  • Men < 40 mg/dL
  • Women < 50 mg/dL Triglycerides ≥150 mg/dL Blood pressure ≥130/≥ 85 mmHg Fasting glucose ≥110-125 mg/dL

Exclusion Criteria:

  • Type 1 or Type 2 diabetes
  • History of heart attack or stroke
  • Pregnant or breastfeeding or planning to become pregnant during the study
  • Cancer (other than non-melanoma skin) within the last 5 years
  • Significant illness requiring medication
  • Inability to read and follow directions in English
  • Donated blood in the last 2 months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Low Methionine 1

    Placebo 2

    Arm Description

    Methionine deficient diet

    Placebo comparator methionine complete diet

    Outcomes

    Primary Outcome Measures

    Weight loss

    Secondary Outcome Measures

    Improve glucose metabolism

    Full Information

    First Posted
    March 18, 2008
    Last Updated
    December 17, 2015
    Sponsor
    Pennington Biomedical Research Center
    Collaborators
    Orentreich Foundation for the Advancement of Science, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00640757
    Brief Title
    Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome
    Official Title
    Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2006 (undefined)
    Primary Completion Date
    December 2008 (Actual)
    Study Completion Date
    December 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Pennington Biomedical Research Center
    Collaborators
    Orentreich Foundation for the Advancement of Science, Inc.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to determine if limiting dietary methionine (MET), one of the 10 essential amino acids (which make up proteins), causes weight loss and/or improves glucose metabolism.
    Detailed Description
    Methionine deficient diets have been shown to increase metabolic rate, decrease weight and extend lifespan in rodents. A methionine deficient diet has been tested for 17 weeks in humans without adverse events and with an average weight loss of 8 kg. This study will test the ability of a low methionine diet to cause weight loss and improve the metabolic syndrome. The metabolic syndrome is driven by insulin resistance which is associated with abdominal fat, so this study hopes to reduce visceral fat, body weight and improve insulin resistance. Twenty-four healthy males or females 21 to 60 years of age, inclusive with a stable weight and a waist circumference >40" in men and >35" in women will participate in this study. Subjects will need at least two of the following: 1) HDL cholesterol < 40 mg/dL in men or < 50 mg/dl in women; 2) triglycerides > 150 mg/dL, 3) blood pressure >130/85 mmHg; 4) fasting glucose 110-125 mg/dL. Subjects who have diabetes, a history of heart attack, stroke, have had cancer in the last five years or take chronic medication for a significant illness will be excluded. Subjects will have a medical history, physical examination, chemistry panel, complete blood count (CBC), electrocardiogram, DEXA, abdominal CT scan to quantitate visceral fat, and blood will be sent to Orentreich for glucose, insulin, C-peptide, lipid profile with particle size, free fatty acids, adiponectin, leptin, high-sensitivity C-reactive protein, and insulin-like growth factor-1. Subjects will also undergo a hyperinsulinemic, euglycemic clamp to quantitate insulin resistance during an 18 hr inpatient stay, and will spend 24 hours in the metabolic chamber to measure metabolic rate. Subjects will then be placed on a diet of Hominex-2, a drink that will give them their protein in an amount based on their body weight, and they will see a dietitian who will give them a list of food they can eat consisting mainly of fruits, vegetables and a small amount of grains. Calories will not be restricted and subjects will receive a choline supplement of 500 mg/d. Subjects will be randomized to receive capsules containing methionine or placebo based on their body weight. The two groups will be on 2mg/kg/d or 23 mg/kg/d of methionine. Participants will return to PBRC every 2 weeks throughout the 16-week diet period to meet with the dietician, have weight and vital signs recorded, and have fasting blood drawn every 4 weeks to be sent to Orentreich for compliance measures. The physical exam, multi-slice CT scan, DEXA, inpatient admission for euglycemic hyperinsulinemic clamp, metabolic chamber stay, and the blood testing obtained at screening and baseline will be repeated at the completion of the 16 week diet period. There are no known risks to the low methionine diet, but some people may have gastrointestinal upsets when they change their diet. The risk of the CT scan is exposure to x-radiation equivalent to a front and side view chest x-ray. The risk of the DEXA is the exposure to x-irradiation equivalent to spending 12 hours in the sunshine. There are no risks to staying in the metabolic chamber. The hyperinsulinemic, euglycemic clamp could cause low blood sugar. This will be avoided by frequent monitoring of blood sugar, and if the low blood sugar were to occur, the test would be stopped and sugar given through the intravenous line. The testing of blood involves the discomfort of a needle going into an arm vein, bruising and rarely fainting or infection. These risks will be minimized by trained technicians using sterile needles.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Metabolic Syndrome
    Keywords
    Methionine, Metabolic syndrome, Glucose Metabolism, Amino acid, Insulin clamp

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    56 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Low Methionine 1
    Arm Type
    Active Comparator
    Arm Description
    Methionine deficient diet
    Arm Title
    Placebo 2
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo comparator methionine complete diet
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Methionine deficient diet
    Other Intervention Name(s)
    Hominex, Methionine
    Intervention Description
    Hominex with a low protein diet
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Methionine sufficient diet
    Other Intervention Name(s)
    Hominex, Methionine capsules, Low protein diet
    Intervention Description
    Hominex, low protein diet and methionine capsules
    Primary Outcome Measure Information:
    Title
    Weight loss
    Time Frame
    Every 2 weeks
    Secondary Outcome Measure Information:
    Title
    Improve glucose metabolism
    Time Frame
    Baseline and end of study

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Male or female between the ages of 21 to 60, inclusive Waist greater than 40 inches for men and 35 inches for women Weight has been stable for at least 6 months (no more than 5 pounds gained or lost) For women of childbearing potential: subject must be willing to use acceptable form of contraception (pill, condom, diaphragm etc.) At least 2 of the following: HDL cholesterol Men < 40 mg/dL Women < 50 mg/dL Triglycerides ≥150 mg/dL Blood pressure ≥130/≥ 85 mmHg Fasting glucose ≥110-125 mg/dL Exclusion Criteria: Type 1 or Type 2 diabetes History of heart attack or stroke Pregnant or breastfeeding or planning to become pregnant during the study Cancer (other than non-melanoma skin) within the last 5 years Significant illness requiring medication Inability to read and follow directions in English Donated blood in the last 2 months.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Thomas W Gettys, Ph.D.
    Organizational Affiliation
    Pennington Biomedical Research Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    21346062
    Citation
    Plaisance EP, Greenway FL, Boudreau A, Hill KL, Johnson WD, Krajcik RA, Perrone CE, Orentreich N, Cefalu WT, Gettys TW. Dietary methionine restriction increases fat oxidation in obese adults with metabolic syndrome. J Clin Endocrinol Metab. 2011 May;96(5):E836-40. doi: 10.1210/jc.2010-2493. Epub 2011 Feb 23.
    Results Reference
    derived

    Learn more about this trial

    Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome

    We'll reach out to this number within 24 hrs